New 2-year data show the long-term effects of bimekizumab on hidradenitis suppurativa, indicating its potential as a valuable ...

UCB, a global biopharmaceutical company, today announced long-term data from the BE HEARD^ trials for BIMZELX®▼ (bimekizumab) in moderate to severe hidradenitis suppurativa (HS). These two-year data, ...

Belgium’s largest drugmaker UCB today released long-term data from the BE HEARD^ trials for Bimzelx (bimekizumab) in moderate ...

Jeffrey Stark, MD, vice president and head of medical immunology at UCB, discusses tailored dosing of bimekizumab-bkzx (Bimzelx) for various inflammatory conditions, highlighting its 5 FDA approvals ...

Fact checked by Nick Blackmer It all started back in the spring of 2018 with a painful bump in my armpit. Confused, scared, ...

From aloe vera to zinc, complementary treatments for hidradenitis suppurativa may pick up where ... own dermatologist before you try something new to treat HS. They can help you figure out which ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.

Stock analysts at Leerink Partnrs lowered their FY2025 earnings estimates for MoonLake Immunotherapeutics in a report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now ...

17."At eight years old, I got my period. Obviously concerned about how young I was, my mom took me to the doctor. The doctor ...